Patents Assigned to Salk Institute for Biological Studies
  • Patent number: 10891313
    Abstract: Methods, devices, and systems are disclosed for producing cognitive and/or sensory profiles. In one aspect, a method to provide a cognitive or sensory assessment of a subject includes selecting a profile category from among a cognitive performance profile, a sensory performance profile, and a cognitive and sensory performance profile, presenting a sequence of stimuli to a subject, the sequence of stimuli based on the selected profile category, acquiring physiological signals of the subject before, during, and after the presenting the sequence of stimuli to produce physiological data, and processing the physiological data to generate an information set including one or more quantitative values associated with the selected profile category.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: January 12, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Todd Prentice Coleman, Rui Ma, Sanggyun Kim, Cheolsoo Park, Ricardo Gil Da Costa, Raynard Fung, Diego Mesa
  • Patent number: 10864217
    Abstract: Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: December 15, 2020
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Lars Pache, Sumit K. Chanda, Mitchell Dennis Vamos, Nicholas David Peter Cosford, Peter Teriete, John Marlett, Arturo Diaz, John A. T. Young
  • Publication number: 20200351232
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: June 3, 2020
    Publication date: November 5, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Publication number: 20200351231
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: June 3, 2020
    Publication date: November 5, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 10822374
    Abstract: Compositions and methods for increasing p53-dependent transcriptional activity in a cell.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: November 3, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Salk Institute for Biological Studies
    Inventors: Loren D. Walensky, Federico Bernal, Geoffrey Wahl, Mark Wade
  • Patent number: 10821141
    Abstract: Recombinant herpes simplex virus (HSV)-1 capable of selectively replicating in alternative lengthening of telomeres (ALT)-dependent tumor cells are described. The recombinant HSV-1 are ICP0-deficient, such as by complete deletion of the ICP0 gene, or mutation of the ICP0 gene sufficient to diminish or eliminate E3 ubiquitin ligase activity of ICP0. In some cases, the recombinant HSV-1 further include additional gene deletions or mutations, such as those that render the virus glycoprotein C (gC) deficient, or include a heterologous gene, such as a gene encoding an immunostimulatory molecule. Methods of treating ALT-dependent cancer, and methods of selectively killing ALT-dependent tumor cells are also described.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: November 3, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Jason DeHart
  • Publication number: 20200339949
    Abstract: Provided herein are, inter alia, are media compositions useful for culturing neural cells. In particular, the compositions provided herein mimic important physiological conditions in the living brain and sustain neural activity. The media compositions provided herein improve the efficiency of human neuron maturation and promote synaptic function in long-term in vitro cultures.
    Type: Application
    Filed: May 14, 2020
    Publication date: October 29, 2020
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Fred H. Gage, Cedric Bardy
  • Patent number: 10815203
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: October 27, 2020
    Assignees: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
  • Patent number: 10806951
    Abstract: The invention provides compositions featuring TRP-4 polypeptides and polynucleotides, methods for expressing such polypeptides and polynucleotides in a cell type of interest, and methods for inducing the activation of the TRP-4 polypeptide in neurons and other cell types using ultrasound.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: October 20, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Sreekanth H. Chalasani, Stuart Ibsen
  • Publication number: 20200325492
    Abstract: Recombinant adenovirus genomes that include an exogenous open reading frame (ORF) and a self-cleaving peptide coding sequence are described. Optimal placement of the exogenous genes for minimal impact on viral kinetics is further disclosed. Therapeutic applications of the recombinant adenoviruses are also described.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 15, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, William Partlo, Colin Powers
  • Publication number: 20200322297
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: June 3, 2020
    Publication date: October 8, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Publication number: 20200308239
    Abstract: Disclosed are probes that are expressed in a cell to label an intracellular target (such as protein or DNA) for both light and electron microscopy. The probes comprise a targeting domain that specifically binds to the intracellular target, a detection tag that can be used to detect the intracellular location of the probe using light microscopy, and a ferritin nanoparticle ferritin nanoparticle with ferroxidase activity and that stores ferric oxide. Also disclosed are nucleic acids encoding the fusion proteins and methods of their use.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Jingwen Yin
  • Patent number: 10774092
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: September 15, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • Patent number: 10745674
    Abstract: The present invention relates to methods for producing polyketide synthase variants, and for altering the activity and/or substrate specificity of putative native and variant polyketide synthases. The present invention further relates to compositions comprising said polyketide synthase variants, compounds prepared using said polyketide synthase variants, and uses of said polyketide synthase variants. In one embodiment, said polyketide synthase variant is 2-pyrone synthase.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: August 18, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Joseph Noel, Kate Woods, Marianne Bowman, Gordon Louie, Nancy Anderson Da Silva, Javier Pascual Cardenas
  • Patent number: 10738325
    Abstract: Recombinant adenovirus genomes that include an exogenous open reading frame (ORF) and a self-cleaving peptide coding sequence are described. Optimal placement of the exogenous genes for minimal impact on viral kinetics is further disclosed. Therapeutic applications of the recombinant adenoviruses are also described.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: August 11, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, William Partlo, Colin Powers
  • Patent number: 10738282
    Abstract: The finding that phosphatidylserine (PtdSer) exposure on the outer leaflet of virally transduced cells triggers their engulfment by resident immune cells is described. It is demonstrated that inhibition of phospholipid scramblase 1 (PLSCR1) activity prevents PtdSer externalization and enables prolonged protection of vector-transduced cells from phagocytosis. Methods of inhibiting a virus vector-induced inflammatory response in tissue, methods of prolonging virus vector encoded transgene expression, and methods of modulating an inflammatory response in tissue of a subject, by administering an inhibitor of PLSCR1 are described.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 11, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Axel Nimmerjahn, Charles L. Clark
  • Publication number: 20200252359
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: March 17, 2020
    Publication date: August 6, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 10729790
    Abstract: The present disclosure relates to nucleic acid promoter sequences that are able to specifically express genes operatively linked to the promoter in brainstem and spinal motor neuron cells, and to methods for using such promoters to selectively express genes in motor neurons in vitro and in vivo. It is based, at least in part, on the discovery that the nucleic acid of SEQ ID NO: 1 functioned as a motor neuron-specific promoter and was successful in expressing transgenes in motor neuron cells in vivo. The present disclosure also relates to compositions that can increase the activity or expression level of miR-218 and to compositions that can decrease the expression of miR-218 target nucleic acids.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: August 4, 2020
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventor: Neal Dilip Amin
  • Publication number: 20200244609
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: January 30, 2020
    Publication date: July 30, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Publication number: 20200216490
    Abstract: Provided herein are deuterated compounds and compositions useful in increasing PPAR? activity. The compounds have a formula where L5 comprises at least one deuterium. Exemplary species include The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: December 17, 2019
    Publication date: July 9, 2020
    Applicant: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes